Sessions
Upstream Bioprocessing Optimisation and Support for Early Development
End-To-End Manufacturing and Downstream Bioprocessing
Reducing Timelines with Innovative Scale Up and Scale Out Technologies
Achieving Operational Excellence in Cell and Gene Therapy Manufacturing
Key Considerations in Cell and Gene Therapy Manufacturing – CMC, Process and Regulatory
Upstream Bioprocessing Optimisation and Support for Early Development
27 Jan 2022
13:30
SPONSORED BY
13:30 Chairperson’s Opening
Mamta Kalra, Director, CMC, Immatics
13:35 : Technology Transfer from Pre-Clinical to cGMP Manufacturing – Take the Time to Develop A Solid Suitable Process From the Start
Lisa McClain Moss, Vice President, Manufacturing, Longeveron
13:50 Closed Cell Sorter System from SONY : An Introduction and Examples of Use in Protocols for Generating Cell Therapy Products Using Multi Parametric Selection
Cedric Ait Mansour, Senior Manager Market Development, Sony Biotechnology Europe
14:20 De-risking Biostorage and Scale with Outsourced Credible Services
- Why and when should outsourced services for biological storage and scale be considered in therapy development?
- What should you look for in selected an experienced provider?
- Regulatory Governance
- Infrastructure
- Advanced Services
Garrie Richardson, General Manager, SciSafe, Part of Biolife Solutions
14:35 Speaker Q&A and Panel Discussion
Speakers
